Pro Matix
Founded 2020 · 17 employees on LinkedIn · 1 known investors
Promatix develops bispecific antibody drug conjugates (ADCs) for solid tumours, using a proteomics-based platform to identify cancer surface marker pairs for cis-bispecific targeting. It is building a pipeline of cancer therapies with a lead program in colorectal cancer.
Founders & leadership
Board
GM
Investors · 1
Companies House · registry record
View on Companies House ↗Insolvency history
- Registered name
- PROMATIX LTD
- Company number
- 09880263
- Status
- Dissolved
- Company type
- Private limited company
- Incorporated
- 19 Nov 2015
- Dissolved
- 4 Oct 2024
- Registered office
- 9ensign House Admirals Way, Marsh Wall, London, E14 9XQ
- Nature of business (SIC)
- 96090 — Other service activities n.e.c.
- Accounts
- last made up to 30 Nov 2022
- Confirmation statement
- last made up to 17 Nov 2022
Current officers
- Christopher Haines Dickson — director, appointed 19 Nov 2015
- Anoop Udayshinh Odedra — director, appointed 19 Nov 2015
Source: Companies House public register · retrieved 9 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does Pro Matix do?
- Promatix develops bispecific antibody drug conjugates (ADCs) for solid tumours, using a proteomics-based platform to identify cancer surface marker pairs for cis-bispecific targeting. It is building a pipeline of cancer therapies with a lead program in colorectal cancer.
- Who are Pro Matix's investors?
- Pro Matix's investors include ALSA Ventures.